Guido Guidi has been since 2017 Founder & Chairman Of AuroraTT, Board Member at Aurora Science, BoD & SAB Member at Zambon Group, Board Member at Genenta, Board Member at Tethis, SAB Member And Consultant at Italfarmaco. He is also a Teaching Professor & Coordinator of the Master in Pharmaceutical Medicine, Milan University and Mario Negri Institute . He is Board Member at Philogen company since June.
From 2012 to 2017, he was Head of Pharma Europe at Novartis, leading Novartis’ General Medicines Business in the European Region, marketing several key products – Cosentyx, Entresto, Lucentis, Gilenya, Xolair, Ultibro, Seebri, Galvus, Exforge, in addition to others – and coordinating the Pharma operations. He was overseeing a staff of more than 7,000 employees operating in more than 50 countries, including Russia and Israel. While being the Head of Pharma Region Europe for 4 years, Novartis Pharma was the leading company in Europe.
From 2002 to 2012, as Head of Novartis Oncology Europe, Guido led the marketing of different oncology products, among which Zometa, Femara, Glivec, Sandostatin and Jakavi. Guido played a key role in various partnering operations as member of the Novartis deal committee, among which Ruxolitinib (Jakavi) from Incyte and Erenumab for the European market from Amgen.
He started his career as a Medical advisor and also had different positions at Sandoz Italia.
Guido has a degree in Medicine from the University of Milan, with a specialization in Immunology & Allergology and Rheumatology. Linkedin Profile